ArticleBMC biotechnology2025
Augmentation of antibacterial activity of ciprofloxacin by bisabololoxide A encapsulated in polymeric nanoparticles against uropathogenic Escherichia coli.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Synthesis, antibacterial, and antibiofilm activities of an adenosine-benzoic acid conjugate against Streptococcus mutans and Escherichia coli: insights from molecular docking.Folia microbiologica · 2026Article
- Anti-biofilm and Efflux Pump Inhibitory Function of FeCurrent microbiology · 2026Article
- Anticancer effects of bisabolol oxide A-Loaded Micellar/Liposomal nanoparticles on DU-145 cells with deregulation of miR-34a and miR-181a: in silico and in vitro studies.BMC biotechnology · 2026Article
- Anticancer activity of an apigenin-functionalized silica-coated silver oxide nanocomposite against human gastric adenocarcinoma cells (AGS): in vitro and in silico analysis.BMC biotechnology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant uropathogenic Escherichia coli (UPEC) are a major cause of urinary tract infections, largely due to efflux pump overexpression, porin alterations, and increasing biofilm formation. To address these challenges, we developed bisabololoxide A-loaded PEG400-oleate polymeric nanoparticles (BAPNs) and evaluated their potential to enhance the efficacy of ciprofloxacin against ciprofloxacin-resistant isolates. MATERIALS AND
methodsBAPNs were synthesized and characterized by FTIR, TEM, FE-SEM, EDX, TGA, and zeta potential analysis. The synergistic effects of BAPNs and ciprofloxacin were evaluated in drug-resistant isolates. The inhibition of Biofilm formationwas quantified by crystal violet staining and gene expression changes in some genes related to efflux pumps, porins and biofilm formation were analyzed in two representative isolates by qPCR.
resultsBAPNs exhibited a spherical morphology with sizes ranging from 17 to 28 nm (TEM) and 30–43 nm (FE-SEM). Checkerboard analysis showed that the MIC of ciprofloxacin decreased by 2- to 32-fold in ciprofloxacin-resistant isolates and the ATCC 8739 strain when combined with BAPNs. Biofilm inhibition was significantly enhanced with the combined therapy compared to ciprofloxacin alone. qPCR analysis further revealed significant downregulation of the AcrAB-TolC efflux pump genes and the virulence genes fimH and hlyA, along with upregulation of the porin genes (ompC and ompF). Furthermore, molecular docking analysis confirmed the strong binding affinities of bisabololoxide A with virulence-associated proteins of E. coli.
conclusionsOur findings suggested that BAPNs may significantly potentiate ciprofloxacin activity by inhibiting efflux pump expression and biofilm formation, and increase of cell membrane permeability to drugs (with enhancing porins), thereby restoring susceptibility in resistant UPEC isolates. These results highlight BAPNs as a promising adjunctive nanocarrier strategy to overcome ciprofloxacin resistance in uropathogenic E. coli. Further validation in larger isolate panels and in vivo studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.